SECENDS - PFE

2025

Q4 4 filings

Nov

Debt Offering

$5B multi-tranche notes, rates 3.875%-5.7%

8-K

Nov

Acquired Metsera

$7.0B enterprise value, up to $20.65/share contingent payments

8-K

Nov

Q3 2025 Results

Unable to extract revenue and EPS - financial data not readable in provided XBRL format

10-Q

Nov

Q3 2025 Earnings

Q3 2025 financial results announced

8-K

Q3 2 filings

Aug

Q2 2025 Results

Revenue and EPS data not available in provided content

10-Q

Aug

Q2 2025 Earnings

Q2 2025 financial results announced

8-K

Q2 4 filings

May

Euro Debt Offering

€3.3B notes issued: 2.875%-4.25% rates, 2029-2045 maturities

8-K

May

Q1 2025 Results

Financial data not accessible in provided format

10-Q

Apr

Q1 Earnings & $1.2B Cost Savings Program

$1.2B additional savings by 2027, $1.6B implementation costs

8-K

Apr

Annual Shareholder Meeting

13 directors elected, auditor ratified, exec comp approved, 2 shareholder proposals rejected

8-K

Q1 3 filings

Mar

2025 Proxy Statement

CEO comp: Not disclosed, Say-on-pay: TBD

DEF 14A

Feb

FY 2024 Results

Unable to extract specific revenue and EPS figures from provided XBRL metadata

📌 Completed acquisition of Seagen in December 2023, with full-year 2024 integration and operations including oncology portfolio expansion

10-K

Feb

Q4 2024 Earnings

Q4 and full-year 2024 financial results announced

8-K

2024

Q4 4 filings

Dec

2025 Guidance Issued

Full-year 2025 guidance provided, 2024 guidance reaffirmed

8-K

Nov

Q3 2024 Results

Unable to extract specific revenue and EPS figures from provided XBRL data

10-Q

Oct

Q3 2024 Earnings

Q3 2024 financial results announced

8-K

Oct

Board Director Election

Mortimer J. Buckley elected to Board

8-K

Q3 5 filings

Aug

Q2 2024 Results

Unable to extract specific revenue and EPS figures from provided XBRL metadata

10-Q

Jul

Q2 2024 Earnings

Q2 2024 financial results announced

8-K

Jul

Executive Compensation Plan Modifications

9,000 employees including 6 named executives get 2-year extensions on TSRUs and PSAs

8-K

Jul

CSO Departure Announced

Dr. Mikael Dolsten stepping down after 15+ years, successor search initiated

8-K

Jul

Board Election

Cyrus Taraporevala elected to Board

8-K

Q2 4 filings

May

Cost Reduction Program Launch

$1.5B savings by 2027, $1.7B one-time costs

8-K

May

Q1 2024 Results

Unable to extract specific revenue and EPS figures from provided XBRL tags

10-Q

May

Q1 2024 Earnings

Q1 2024 financial results announced

8-K

Apr

Annual Shareholder Meeting

All 12 directors elected, auditor ratified, executive comp approved

8-K

Q1 4 filings

Mar

2024 Proxy Statement

CEO comp: Not disclosed, Say-on-pay: TBD

DEF 14A

Feb

FY2023 2023 Results

Unable to extract specific revenue and EPS figures from provided XBRL metadata

📌 Completed acquisition of Seagen on December 14, 2023, adding significant oncology capabilities to Pfizer's pipeline

10-K

Jan

Q4 2023 Earnings

Q4 and full-year 2023 financial results announced

8-K

Jan

Mini-Tender Offer Received

TRC Capital offers $27.35/share for 4M shares, 4.4% below market

8-K